Applying an equity lens to pharmacogenetic research and translation to under‐represented populations

Abstract Since the publication of the Human Genome Project, genetic information has been used as an accepted, evidence‐based biomarker to optimize patient care through the delivery of precision health. Pharmacogenetics (PGx) uses information about genes that encode proteins involved in pharmacokinet...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tiana Luczak, David Stenehjem, Jacob Brown
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/01706e9b3401492586aa6d711cc72e8f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:01706e9b3401492586aa6d711cc72e8f
record_format	dspace
spelling	oai:doaj.org-article:01706e9b3401492586aa6d711cc72e8f2021-11-19T17:51:34ZApplying an equity lens to pharmacogenetic research and translation to under‐represented populations1752-80621752-805410.1111/cts.13110https://doaj.org/article/01706e9b3401492586aa6d711cc72e8f2021-11-01T00:00:00Zhttps://doi.org/10.1111/cts.13110https://doaj.org/toc/1752-8054https://doaj.org/toc/1752-8062Abstract Since the publication of the Human Genome Project, genetic information has been used as an accepted, evidence‐based biomarker to optimize patient care through the delivery of precision health. Pharmacogenetics (PGx) uses information about genes that encode proteins involved in pharmacokinetics, pharmacodynamics, and hypersensitivity reactions to guide clinical decision making to optimize medication therapy selection. Clinical PGx implementation is growing from the dramatic increase in PGx studies over the last decade. However, an overwhelming lack of genetic diversity in current PGx studies is evident. This lack of diverse representation in PGx studies will impede equitable clinical implementation through potentially inappropriate application of gene‐based dosing algorithms, whereas representing a missed opportunity for identification of population specific single nucleotide variants and alleles. In this review, we discuss the challenges of studying PGx in under‐represented populations, highlight two successful PGx studies conducted in non‐European populations, and propose a path forward through community‐based participatory research for equitable PGx research and clinical translation.Tiana LuczakDavid StenehjemJacob BrownWileyarticleTherapeutics. PharmacologyRM1-950Public aspects of medicineRA1-1270ENClinical and Translational Science, Vol 14, Iss 6, Pp 2117-2123 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270
spellingShingle	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270 Tiana Luczak David Stenehjem Jacob Brown Applying an equity lens to pharmacogenetic research and translation to under‐represented populations
description	Abstract Since the publication of the Human Genome Project, genetic information has been used as an accepted, evidence‐based biomarker to optimize patient care through the delivery of precision health. Pharmacogenetics (PGx) uses information about genes that encode proteins involved in pharmacokinetics, pharmacodynamics, and hypersensitivity reactions to guide clinical decision making to optimize medication therapy selection. Clinical PGx implementation is growing from the dramatic increase in PGx studies over the last decade. However, an overwhelming lack of genetic diversity in current PGx studies is evident. This lack of diverse representation in PGx studies will impede equitable clinical implementation through potentially inappropriate application of gene‐based dosing algorithms, whereas representing a missed opportunity for identification of population specific single nucleotide variants and alleles. In this review, we discuss the challenges of studying PGx in under‐represented populations, highlight two successful PGx studies conducted in non‐European populations, and propose a path forward through community‐based participatory research for equitable PGx research and clinical translation.
format	article
author	Tiana Luczak David Stenehjem Jacob Brown
author_facet	Tiana Luczak David Stenehjem Jacob Brown
author_sort	Tiana Luczak
title	Applying an equity lens to pharmacogenetic research and translation to under‐represented populations
title_short	Applying an equity lens to pharmacogenetic research and translation to under‐represented populations
title_full	Applying an equity lens to pharmacogenetic research and translation to under‐represented populations
title_fullStr	Applying an equity lens to pharmacogenetic research and translation to under‐represented populations
title_full_unstemmed	Applying an equity lens to pharmacogenetic research and translation to under‐represented populations
title_sort	applying an equity lens to pharmacogenetic research and translation to under‐represented populations
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/01706e9b3401492586aa6d711cc72e8f
work_keys_str_mv	AT tianaluczak applyinganequitylenstopharmacogeneticresearchandtranslationtounderrepresentedpopulations AT davidstenehjem applyinganequitylenstopharmacogeneticresearchandtranslationtounderrepresentedpopulations AT jacobbrown applyinganequitylenstopharmacogeneticresearchandtranslationtounderrepresentedpopulations
_version_	1718419992365498368

Applying an equity lens to pharmacogenetic research and translation to under‐represented populations

Ejemplares similares